Calliditas Therapeutics P/E 2024

Calliditas Therapeutics Aktienanalyse

What does Calliditas Therapeutics do?

Calliditas Therapeutics AB was founded in 2004 and is headquartered in Stockholm, Sweden. The company's goal is to develop innovative therapies for rare diseases and treat patients worldwide. The company is divided into two main business areas: clinical development and commercial products. The clinical development area focuses on identifying, developing, and marketing drugs for the treatment of kidney and liver diseases, as well as autoimmune diseases. The commercial products area distributes the developed medications. Calliditas' business model is based on the discovery and exploration of therapies for rare diseases. The company divides its pipeline into different product categories such as kidney and liver diseases, as well as autoimmune diseases. It is expected that this pipeline will make further progress over time and bring several products to market. Currently, Calliditas is in Phase 3 of clinical trials for Nefecon, a medication for the treatment of IgA nephropathy. IgA nephropathy is a rare kidney disease in which immunoglobulin A deposits in the kidneys can cause inflammation and damage. Nefecon is being developed to reduce the production of IgA and thereby reduce inflammation in the kidneys. Calliditas is also in Phase 2 of clinical trials for Atimmune, a medication for the treatment of autoimmune diseases. Atimmune aims to modulate the immune system to treat autoimmune diseases naturally. In addition, Calliditas is currently working on another medication for the treatment of liver diseases called FT-4202. FT-4202 is intended to increase the production of hemoglobin and thereby alleviate the symptoms of sickle cell anemia. Calliditas has an experienced team of researchers, clinicians, and salespeople dedicated to the development of medications for rare diseases. The company collaborates closely with experts in the field of kidney and liver diseases, as well as autoimmune diseases, to improve the development and marketing of its products. The company has also formed partnerships with other companies and industry stakeholders to support its research and development efforts. For example, Calliditas has entered into an agreement with Everest Medicines Ltd., a Chinese biotech company specializing in rare diseases, to market and distribute Nefecon in China. Overall, Calliditas has a promising pipeline of medications for the treatment of rare diseases. The company is well positioned to succeed in the coming years and improve the lives of patients around the world. Calliditas Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Calliditas Therapeutics's P/E Ratio

The Price to Earnings (P/E) Ratio of Calliditas Therapeutics is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Calliditas Therapeutics's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Calliditas Therapeutics is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Calliditas Therapeutics’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Calliditas Therapeutics stock

What is the price-to-earnings ratio of Calliditas Therapeutics?

The price-earnings ratio of Calliditas Therapeutics is currently 70.86.

How has the price-earnings ratio of Calliditas Therapeutics changed compared to last year?

The price-to-earnings ratio of Calliditas Therapeutics has increased by -758.55% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Calliditas Therapeutics high compared to other companies?

Yes, the price-to-earnings ratio of Calliditas Therapeutics is high compared to other companies.

How does an increase in the price-earnings ratio of Calliditas Therapeutics affect the company?

An increase in the price-earnings ratio of Calliditas Therapeutics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Calliditas Therapeutics affect the company?

A decrease in the price-earnings ratio of Calliditas Therapeutics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Calliditas Therapeutics?

Some factors that influence the price-earnings ratio of Calliditas Therapeutics are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Calliditas Therapeutics pay?

Over the past 12 months, Calliditas Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Calliditas Therapeutics is expected to pay a dividend of 0 SEK.

What is the dividend yield of Calliditas Therapeutics?

The current dividend yield of Calliditas Therapeutics is .

When does Calliditas Therapeutics pay dividends?

Calliditas Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Calliditas Therapeutics?

Calliditas Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Calliditas Therapeutics?

For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.

In which sector is Calliditas Therapeutics located?

Calliditas Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Calliditas Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Calliditas Therapeutics from 7/8/2024 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 7/8/2024.

When did Calliditas Therapeutics pay the last dividend?

The last dividend was paid out on 7/8/2024.

What was the dividend of Calliditas Therapeutics in the year 2023?

In the year 2023, Calliditas Therapeutics distributed 0 SEK as dividends.

In which currency does Calliditas Therapeutics pay out the dividend?

The dividends of Calliditas Therapeutics are distributed in SEK.